Acetylsalicylic Acid Calcium - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Acetylsalicylic Acid Calcium

The Experts below are selected from a list of 9 Experts worldwide ranked by ideXlab platform

Acetylsalicylic Acid Calcium – Free Register to Access Experts & Abstracts

M. Galimzyaynov – One of the best experts on this subject based on the ideXlab platform.

  • The influence of melaxen on the function of thrombocytes in the experimental hypo- and hyperaggregation
    , 2013
    Co-Authors: M. Galimzyaynov
    Abstract:

    The work presents the data which were obtained in the experimental study of the regulatory action of the synthetic analog of melatonin – melaxen – on the functioning of the thrombocytes under conditions of hypo- and hyperaggregation. Hypoaggregation`s model of the thrombocytes dysfunction induced by introduction of Acetylsalicylic Acid (per os in dose of 20 mg/kg). Hyperaggregation was caused by the intraperitoneal injection of 0.1 ml of a 10% solution of Calcium chloride. We studied the activity of melaxen in doses of 1 mg/kg and 10 mg/kg. In our experimental work was found that melaxen in dose 1 mg/kg has correcting capability, reducing dysfunction of the thrombocytes which formed in experimental hypo- and hyperaggregation.Key words: melaxen, thrombocytes, disruption of homeostasis, Acetylsalicylic Acid, Calcium chloride.Действие ионизирующего излучения приводит к истощению пула стволовых клеток, увеличивает нагрузку на дифференцированные клетки, в результате усиливаются процессы репарации и апоптоза. Наряду с хорошо документированными острыми эффектами, радиотерапия приводит и к отсроченным, проявляющимся спустя годы после успешного лечения. Целью нашей работы было формирование и апробация комплекса тестов для определения последствий облучения с учетом различной радиочувстви-тельности организма. Наблюдали общий сдвиг вклада в светорассеяния в сторону более мелких частиц у линий 101/Hf и C3Н/Sn, тогда как у мышей линии С57BL отмечали увеличение доли частиц большего диаметра. Гистологическое исследование показало, что в печени мышей линии С57BL, в отличие от дру-гих линий, отмечается уменьшение частоты встречаемости тяжелых повреждений к окончанию экспери-мента. Такая же тенденция у этой линии обнаружена в ткани поджелудочной железы, а противоположная – в ткани селезенки. Таким образом, мыши линии С57BL реагируют на облучение намного позже, чем линии 101/Hf и C3Н/Sn, при этом их адаптивность достаточно высока. Животные линии C3Н/Sn лучше всех выходят из радиационного кризиса. Ключевые слова: облучение, межлинейные различия, лазерная корреляционная спектроскопия.

T.s. Petersen – One of the best experts on this subject based on the ideXlab platform.

  • Deprescribing potentially inappropriate medication in cancer patients
    Annals of Oncology, 2019
    Co-Authors: S.b. Reuter, T.s. Petersen
    Abstract:

    Abstract Background Due to their advanced age many cancer patients with unfavorable prognosis suffer from comorbidities, and thus the risk of consuming potentially inappropriate medication (PIM). It is vital to deprescribe drugs with potential harmful effects or no short-term benefit for lowering pill. Hence, we examined the degree of deprescription of potentially inappropriate medication (PIM) in patients suffering from cancer. Methods Retrospective, register-based study of all patients with newly diagnosed breast, prostate, pancreatic, and lung cancer, diagnosed at a hospital in the Capital Region of Denmark (1.8 million inhabitants) from 2012-2014. Patients with insufficient staging information or other malignancy except non-melanoma skin-cancer were excluded. Information about medication, comorbidity and mortality was extracted from the electronic health records. PIM were defined as: Acetylsalicylic Acid, Calcium channel blockers, statins, thiazides, and bisphosphonates. The study was approved by the Danish Patient Safety Authority (No. 3-3013-1884/1/) and the Danish Data Protection Agency (No. BFH-2016-058). Results Table . 1607P Breast (n = 3,959)/prostate cancer (n = 3,535) (total n = 7,494) Lung (n = 2,824)/pancreatic cancer (n = 617) (n = 3,441) Gender (Women) 52% 50% Age mean (sd) 65 (12) 70 (10) 1-year Survival 97% 46% Metastatic disease 6.7% 52% Co-morbidities Diabetes 4.0 % 9.7 % Hypertension 12 % 23 % Atrial fibrillation 4.7 % 8.7 % Ischemic heart disease 6.4 % 11.6 % Heart failure 2.2 % 5.6 % Ischemic stroke 1.5 % 2.8 % Medication 1-year deprescription/total treated § Acetylsalicylic Acid 250/1,443 (17%) 398/928 (43%) Calcium channel blockers 135/1,048 (13%) 284/659 (43%) Statins 187/1,769 (11%) 501/1,066 (47%) Thiazide diuretics 175/954 (18%) 259/534 (49%) Bisphosphonates 26/319 (8.2%) 64/171 (37%) (Patients not surviving 1 year and treatment continuing until death does not count towards deprescribed) § Deprescribed during the first year after cancer-diagnosis/total number of patients treated Conclusions Our findings show that oncologists and physicians have a rational approach to deprescription in patients suffering from cancer with short-term (pancreatic and lung cancer) respectively long-term (breast and prostate cancer) survival rates. However, several patients were continuing potential inappropriate medications in the terminal stage of cancer. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.

S.b. Reuter – One of the best experts on this subject based on the ideXlab platform.

  • Deprescribing potentially inappropriate medication in cancer patients
    Annals of Oncology, 2019
    Co-Authors: S.b. Reuter, T.s. Petersen
    Abstract:

    Abstract Background Due to their advanced age many cancer patients with unfavorable prognosis suffer from comorbidities, and thus the risk of consuming potentially inappropriate medication (PIM). It is vital to deprescribe drugs with potential harmful effects or no short-term benefit for lowering pill. Hence, we examined the degree of deprescription of potentially inappropriate medication (PIM) in patients suffering from cancer. Methods Retrospective, register-based study of all patients with newly diagnosed breast, prostate, pancreatic, and lung cancer, diagnosed at a hospital in the Capital Region of Denmark (1.8 million inhabitants) from 2012-2014. Patients with insufficient staging information or other malignancy except non-melanoma skin-cancer were excluded. Information about medication, comorbidity and mortality was extracted from the electronic health records. PIM were defined as: Acetylsalicylic Acid, Calcium channel blockers, statins, thiazides, and bisphosphonates. The study was approved by the Danish Patient Safety Authority (No. 3-3013-1884/1/) and the Danish Data Protection Agency (No. BFH-2016-058). Results Table . 1607P Breast (n = 3,959)/prostate cancer (n = 3,535) (total n = 7,494) Lung (n = 2,824)/pancreatic cancer (n = 617) (n = 3,441) Gender (Women) 52% 50% Age mean (sd) 65 (12) 70 (10) 1-year Survival 97% 46% Metastatic disease 6.7% 52% Co-morbidities Diabetes 4.0 % 9.7 % Hypertension 12 % 23 % Atrial fibrillation 4.7 % 8.7 % Ischemic heart disease 6.4 % 11.6 % Heart failure 2.2 % 5.6 % Ischemic stroke 1.5 % 2.8 % Medication 1-year deprescription/total treated § Acetylsalicylic Acid 250/1,443 (17%) 398/928 (43%) Calcium channel blockers 135/1,048 (13%) 284/659 (43%) Statins 187/1,769 (11%) 501/1,066 (47%) Thiazide diuretics 175/954 (18%) 259/534 (49%) Bisphosphonates 26/319 (8.2%) 64/171 (37%) (Patients not surviving 1 year and treatment continuing until death does not count towards deprescribed) § Deprescribed during the first year after cancer-diagnosis/total number of patients treated Conclusions Our findings show that oncologists and physicians have a rational approach to deprescription in patients suffering from cancer with short-term (pancreatic and lung cancer) respectively long-term (breast and prostate cancer) survival rates. However, several patients were continuing potential inappropriate medications in the terminal stage of cancer. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.

E.a. Heldeweg – One of the best experts on this subject based on the ideXlab platform.

  • Het perioperatieve antistollingsbeleid in de urologische praktijk in Nederland
    Tijdschrift voor Urologie, 2013
    Co-Authors: M.m. Dijk, E.p. Haarst, M.s. Lambooij, E.a. Heldeweg
    Abstract:

    The perioperative anticoagulant management in urological practice in the Netherlands Introduction: If patients requiring surgery use anticoagulant therapy, decisions should be made whether to stop or to continue this therapy. The risk of bleeding should be weighed against the risk of thrombosis. Recent guidelines recommend continuing carbasalate Calcium, unless minimal bleeding causes serious damage. The purpose of this study was to investigate the perioperative anticoagulant management in urological practice in the Netherlands. Materials: An online survey was e-mailed to all Dutch urologists. It was asked what medication (acenocoumarol, phenprocoumon, clopidogrel, Acetylsalicylic Acid, Calcium carbasalate and dipyridamol) is stopped prior to various urological surgeries. Results: The perioperative management is consistent concerning vitamin K antagonists and clopidogrel. The policy concerning carbasalate Calcium is not consistent. Carbasalate Calcium is more often discontinued than guidelines recommend. Conclusions: The perioperative management concerning carbasalate Calcium is not consistent. Consensus on the optimal perioperative anticoagulation policy is needed. Research on the surgical risks of continuing anticoagulant therapy is warranted. Introductie: Indien een patiënt die een operatieve ingreep moet ondergaan een vitamine K-antagonist of trombocytenaggregatieremmer gebruikt, zal besloten moeten worden of de patiënt deze medicatie moet stoppen, of kan continueren. Het risico van bloedingscomplicaties moet worden afgezet tegen het tromboserisico. Recente richtlijnen adviseren carbasalaatCalcium perioperatief te continueren, tenzij minimale bloedingen ernstige gevolgen hebben. Het doel van deze studie was het perioperatieve antistollingsbeleid in de urologische praktijk in Nederland te inventariseren. Materiaal: Per e-mail is een online enquête naar alle urologen in Nederland gestuurd. Nagevraagd is welke medicatie (acenocoumarol, fenprocoumon, clopidogrel, acetylsalicylzuur, carbasalaatCalcium en dipyridamol) gestaakt wordt bij verschillende urologische ingrepen. Resultaten: Het perioperatieve beleid is consistent bij de vitamine K-antagonisten en clopidogrel. Bij carbasalaatCalcium is dat niet het geval. Behandeling met carbasalaatCalcium wordt vaker gestaakt dan in de meeste richtlijnen wordt geadviseerd. Conclusies: Het perioperatieve beleid bij carbasalaatCalciumgebruik is niet consistent. Consensus over het optimale perioperatieve antistollingsbeleid is wenselijk. Onderzoek naar de chirurgische risico’s van het continueren van antistollingstherapie is nodig.

M.m. Dijk – One of the best experts on this subject based on the ideXlab platform.

  • Het perioperatieve antistollingsbeleid in de urologische praktijk in Nederland
    Tijdschrift voor Urologie, 2013
    Co-Authors: M.m. Dijk, E.p. Haarst, M.s. Lambooij, E.a. Heldeweg
    Abstract:

    The perioperative anticoagulant management in urological practice in the Netherlands Introduction: If patients requiring surgery use anticoagulant therapy, decisions should be made whether to stop or to continue this therapy. The risk of bleeding should be weighed against the risk of thrombosis. Recent guidelines recommend continuing carbasalate Calcium, unless minimal bleeding causes serious damage. The purpose of this study was to investigate the perioperative anticoagulant management in urological practice in the Netherlands. Materials: An online survey was e-mailed to all Dutch urologists. It was asked what medication (acenocoumarol, phenprocoumon, clopidogrel, Acetylsalicylic Acid, Calcium carbasalate and dipyridamol) is stopped prior to various urological surgeries. Results: The perioperative management is consistent concerning vitamin K antagonists and clopidogrel. The policy concerning carbasalate Calcium is not consistent. Carbasalate Calcium is more often discontinued than guidelines recommend. Conclusions: The perioperative management concerning carbasalate Calcium is not consistent. Consensus on the optimal perioperative anticoagulation policy is needed. Research on the surgical risks of continuing anticoagulant therapy is warranted. Introductie: Indien een patiënt die een operatieve ingreep moet ondergaan een vitamine K-antagonist of trombocytenaggregatieremmer gebruikt, zal besloten moeten worden of de patiënt deze medicatie moet stoppen, of kan continueren. Het risico van bloedingscomplicaties moet worden afgezet tegen het tromboserisico. Recente richtlijnen adviseren carbasalaatCalcium perioperatief te continueren, tenzij minimale bloedingen ernstige gevolgen hebben. Het doel van deze studie was het perioperatieve antistollingsbeleid in de urologische praktijk in Nederland te inventariseren. Materiaal: Per e-mail is een online enquête naar alle urologen in Nederland gestuurd. Nagevraagd is welke medicatie (acenocoumarol, fenprocoumon, clopidogrel, acetylsalicylzuur, carbasalaatCalcium en dipyridamol) gestaakt wordt bij verschillende urologische ingrepen. Resultaten: Het perioperatieve beleid is consistent bij de vitamine K-antagonisten en clopidogrel. Bij carbasalaatCalcium is dat niet het geval. Behandeling met carbasalaatCalcium wordt vaker gestaakt dan in de meeste richtlijnen wordt geadviseerd. Conclusies: Het perioperatieve beleid bij carbasalaatCalciumgebruik is niet consistent. Consensus over het optimale perioperatieve antistollingsbeleid is wenselijk. Onderzoek naar de chirurgische risico’s van het continueren van antistollingstherapie is nodig.